Catalyst Health Economics Consultants

Seasonal Allergic Conjunctivitis

1. Health economic impact of using olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK.

Authors: JF Guest, JP Clegg, and AF Smith.
Source: Current Medical Research & Opinion 2006 ; 22(9): 1777-1785 2006; in press.

View Abstract

2. Modelling the health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK.

Presented at the 9th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Copenhagen, October 2006 and published in Value in Health 2006; 9(6): A367. Abstract PEY7.


<<< Go Back

Catalyst Health Economics Consultants Ltd
© 1991 - 2018